[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201907260PA - Physiologically active substance carrier - Google Patents

Physiologically active substance carrier

Info

Publication number
SG11201907260PA
SG11201907260PA SG11201907260PA SG11201907260PA SG11201907260PA SG 11201907260P A SG11201907260P A SG 11201907260PA SG 11201907260P A SG11201907260P A SG 11201907260PA SG 11201907260P A SG11201907260P A SG 11201907260PA SG 11201907260P A SG11201907260P A SG 11201907260PA
Authority
SG
Singapore
Prior art keywords
active substance
physiologically active
substance carrier
bioactive substance
silica particles
Prior art date
Application number
SG11201907260PA
Inventor
Cheolhee Won
Original Assignee
Lemonex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lemonex Inc filed Critical Lemonex Inc
Priority claimed from PCT/KR2018/001617 external-priority patent/WO2018143787A1/en
Publication of SG11201907260PA publication Critical patent/SG11201907260PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • C01B33/18—Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • C01B33/124—Preparation of adsorbing porous silica not in gel form and not finely divided, i.e. silicon skeletons, by acidic treatment of siliceous materials
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/30—Particle morphology extending in three dimensions
    • C01P2004/32—Spheres
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/62—Submicrometer sized, i.e. from 0.1-1 micrometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/12—Surface area

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicon Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)

Abstract

22 【】 The present invention provides a bioactive substance carrier, which includes: a bioactive substance; and porous silica particles supporting the bioactive substance and having a plurality of pores with a diameter of 5 nm to 100 5 nm, wherein the porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered. 10 Fig.8
SG11201907260PA 2017-02-06 2018-02-06 Physiologically active substance carrier SG11201907260PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455148P 2017-02-06 2017-02-06
PCT/KR2018/001617 WO2018143787A1 (en) 2017-02-06 2018-02-06 Physiologically active substance carrier
KR1020180014842A KR20180091768A (en) 2017-02-06 2018-02-06 Bioactive substance deleviry carrier

Publications (1)

Publication Number Publication Date
SG11201907260PA true SG11201907260PA (en) 2019-09-27

Family

ID=63443663

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907260PA SG11201907260PA (en) 2017-02-06 2018-02-06 Physiologically active substance carrier

Country Status (11)

Country Link
US (2) US11129796B2 (en)
EP (1) EP3578171A4 (en)
JP (2) JP6883354B2 (en)
KR (1) KR20180091768A (en)
CN (1) CN110475546A (en)
AU (2) AU2018216591B2 (en)
BR (1) BR112019016281A2 (en)
CA (1) CA3052561C (en)
MX (1) MX2019009271A (en)
PH (1) PH12019550145A1 (en)
SG (1) SG11201907260PA (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173074A4 (en) 2014-07-22 2018-03-07 Lemonex Inc. Composition for delivering bioactive material or protein, and use thereof
EP3578171A4 (en) * 2017-02-06 2020-12-30 Lemonex Inc. Physiologically active substance carrier
CN116059171A (en) * 2017-07-25 2023-05-05 雷莫内克斯生物制药有限公司 Composition for delivering physiologically active ingredient to blood vessel
KR102152348B1 (en) 2017-09-05 2020-09-08 주식회사 레모넥스 Composition for modulating cell fate
WO2020027571A1 (en) * 2018-07-31 2020-02-06 주식회사 레모넥스 Pharmaceutical composition for wound healing
WO2020032366A1 (en) * 2018-08-06 2020-02-13 주식회사 레모넥스 Immunoreactant carrier
CN112543631B (en) * 2018-08-06 2022-12-06 雷莫内克斯生物制药有限公司 Immunoreactive substance carrier
CN113631264A (en) * 2019-03-29 2021-11-09 住友化学株式会社 Inorganic porous support and method for producing nucleic acid using same
EP3950125A4 (en) * 2019-03-29 2023-01-04 Sumitomo Chemical Company Limited Porous inorganic carrier and method for producing nucleic acid using same
JP7450292B2 (en) * 2020-07-03 2024-03-15 レモネックス インコーポレイテッド RNA and nucleic acid carriers containing it
CN113189329A (en) * 2020-10-14 2021-07-30 北京化工大学 Multiple immunity colorimetric virus detection method based on monatomic nanoenzyme
CN118524825A (en) * 2022-02-03 2024-08-20 株式会社资生堂 External composition for skin
CN115337306B (en) * 2022-09-20 2023-10-20 河南大学 Application of dihydroergotoxine mesylate targeted STAT3 in preparation of anti-inflammatory diseases and anti-tumor drugs
CN116920003B (en) * 2023-08-29 2024-06-07 河北瑞龙生物科技有限公司 Method for extracting total flavonoids from evening primrose

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
EP3556401A1 (en) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
EP2056794A4 (en) 2006-08-08 2012-12-26 Univ Texas Multistage delivery of active agents
WO2009078924A2 (en) 2007-12-06 2009-06-25 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
KR100950548B1 (en) * 2008-01-10 2010-03-30 연세대학교 산학협력단 A porous hollow silica nanoparticle, preparation method thereof, drug carrier and pharmacetical composition comprising the same
US8012508B2 (en) 2008-01-15 2011-09-06 Abbott Cardiovascular Systems Inc. Method of targeting sustained release formulations of therapeutic agents to treat lung diseases
AU2009224418B2 (en) 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
KR101057116B1 (en) 2008-06-17 2011-08-16 한국과학기술원 Differentiation regulators and differentiation control methods in mammals
US8252337B2 (en) 2008-10-23 2012-08-28 National Health Research Institutes Charged mesoporous silica nanoparticle-based drug delivery system for controlled release and enhanced bioavailability
KR101137886B1 (en) 2009-04-24 2012-04-25 조선대학교산학협력단 Image diagnostic drug delivery carrier using porous silicon particles and manufacturing method thereof
KR101087262B1 (en) 2009-06-26 2011-11-29 한국외국어대학교 연구산학협력단 Hollow mesoporous silica capsule and method for preparing the same
FR2952368B1 (en) 2009-11-10 2012-01-13 Commissariat Energie Atomique SILICA PARTICLE INCORPORATING A MOLECULE OF INTEREST, PROCESS FOR PREPARING THE SAME AND USES THEREOF
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
US20110256184A1 (en) 2010-04-14 2011-10-20 Battelle Memorial Institute Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release
KR20120025224A (en) 2010-09-07 2012-03-15 인하대학교 산학협력단 Drug delivery sysetm comprising mesoporous silica nanoparticles and cyclodextrine
CA2834365A1 (en) 2011-04-28 2012-11-01 Sandia Corporation Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
CA2852064A1 (en) 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
US20140014327A1 (en) 2012-07-13 2014-01-16 Schlumberger Technology Corporation Methodology and system for producing fluids from a condensate gas reservoir
KR101388958B1 (en) 2012-07-16 2014-04-24 서울대학교산학협력단 Composition for drug delivery and drug delivery method using the same
KR101528197B1 (en) 2013-07-29 2015-06-15 서강대학교산학협력단 pH-responsive Mesoporous Silica Nanoparticle Coated with Chitosan
CN103751857A (en) 2014-01-22 2014-04-30 同济大学 Drug-loaded silica embolism microsphere and preparation method thereof
EP3173074A4 (en) 2014-07-22 2018-03-07 Lemonex Inc. Composition for delivering bioactive material or protein, and use thereof
CN105560186A (en) * 2014-10-13 2016-05-11 卫生部北京医院 Slow-release medicinal preparation for treating heart diseases
EP3270932B1 (en) 2015-03-16 2024-08-21 PDX Pharmaceuticals, Inc. Cross-linked polymer modified nanoparticles
KR101724142B1 (en) 2015-05-22 2017-04-18 차의과학대학교 산학협력단 Composition for drug delivery, method for the preparation thereof, and drug delivery method using the same
JP6894423B2 (en) 2015-07-09 2021-06-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ Fusible liposome-coated porous silicon nanoparticles
EP3750624A1 (en) 2015-11-02 2020-12-16 The University of North Carolina at Chapel Hill Functionalized mesoporous silica via an aminosilane surfactant ion exchange reaction: controlled scaffold design and nitric oxide release
CN105456198B (en) * 2015-12-25 2017-04-26 正大天晴药业集团股份有限公司 Entecavir-loaded mesoporous silica nanoparticle and preparation method thereof
KR101924519B1 (en) 2016-06-08 2018-12-04 광주과학기술원 Peptide-chitosan modified nanoparticle and drug carrier comprising the same
KR101754798B1 (en) 2016-07-28 2017-07-06 한국과학기술원 Composition for inducing the differentiation into m2 macrophage comprising mesoporus silica nanopaticles and cytokine contained therein
KR101762825B1 (en) 2016-08-08 2017-07-28 한국과학기술원 Composition for anti-inflammation comprising mesoporus silica nanoparticles and cytokine contained therein
EP3578171A4 (en) * 2017-02-06 2020-12-30 Lemonex Inc. Physiologically active substance carrier
CN116059171A (en) 2017-07-25 2023-05-05 雷莫内克斯生物制药有限公司 Composition for delivering physiologically active ingredient to blood vessel

Also Published As

Publication number Publication date
AU2018216591B2 (en) 2021-07-22
AU2021232725A1 (en) 2021-10-14
EP3578171A4 (en) 2020-12-30
AU2021232725B2 (en) 2023-07-20
PH12019550145A1 (en) 2020-06-08
BR112019016281A2 (en) 2020-04-14
JP2021143177A (en) 2021-09-24
JP2020506972A (en) 2020-03-05
CA3052561A1 (en) 2018-08-09
US20240041771A1 (en) 2024-02-08
US11129796B2 (en) 2021-09-28
AU2018216591A1 (en) 2019-08-29
JP7360727B2 (en) 2023-10-13
US20200009054A1 (en) 2020-01-09
MX2019009271A (en) 2019-10-30
EP3578171A1 (en) 2019-12-11
CA3052561C (en) 2023-02-14
JP6883354B2 (en) 2021-06-09
CN110475546A (en) 2019-11-19
US11793757B2 (en) 2023-10-24
US20210369614A1 (en) 2021-12-02
KR20180091768A (en) 2018-08-16

Similar Documents

Publication Publication Date Title
SG11201907260PA (en) Physiologically active substance carrier
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
WO2017091749A8 (en) Shape changing drug delivery devices and methods
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021006912A (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof.
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019005127A (en) Mesenchymal stem cells populations, their products, and use thereof.
MX2011008383A (en) Synthetic rna-based agonists of tlr7.
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2015154082A8 (en) Refillable drug delivery devices and methods of use thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2016014622A (en) Drug delivery systems and related methods of use.
ZA201502979B (en) A porous silica material for use as a pharmaceutical or dietary active ingredient
IN2015KN00005A (en)
IN2014DN06817A (en)
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
TN2016000207A1 (en) Pharmaceutical dosage forms.
PH12015500374A1 (en) Extended release compositions of an aminoalkyl nitrate
MX2018004445A (en) Colloidal particles for use in medicine.
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction